Method for improving respiratory function and inhibiting muscular degeneration
AssigneeChildren's Medical Center Corporation
InventorYang D. Teng
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for improving respiratory function and inhibiting muscular degeneration (e.g., dystrophy and atrophy). Alternative embodiments of the invention provide a method of inhibiting motor neuron apoptosis and the subsequent muscular degeneration associated with the denervation of muscular tissue resulting from neuron death.
Claims11
A method of improving respiratory function in an individual with abnormal respiratory function resulting from spinal cord respiratory motor neuron injury or degeneration comprising administering an agent selected from the group consisting of:
- a serotonin (5HT) receptor type 1A agonist and a β2-adrenergic agonist, wherein the β2-adrenergic agonist is selected from the group consisting of clenbuterol and salbutamol and wherein the serotonin (5HT) receptor type 1A agonist is selected from the group consisting of 8-OH-DPAT and buspirone.
A method of treating an individual with ALS induced respiratory abnormalities to restore respiratory function comprising administering a serotonin (5HT) receptor type 1A agonist a combination with a β2-adrenergic agonist, wherein the serotonin (5HT) receptor type 1A agonist is selected from the group consisting of 8-OH-DPAT and buspirone an wherein the β2-adrenergic agonist is selected from the group consisting of clenbuterol and salbutamol.
A method of improving respiratory abnormalities in an individual afflicted with ALS induced respiratory abnormalities comprising administering a serotonin (5HT) receptor type 1A agonist in combination with a β2-adrenergic agonist, wherein the serotonin (5HT) receptor type 1A agonist is selected from the group consisting of 8-OH-DPAT and buspirone and wherein the β2-adrenergic agonist is selected front the group consisting of clenbuterol and salbutamol.
A method of treating an individual with spinal cord injury induced respiratory abnormalities by administering a serotonin (5HT) receptor type 1A agonist, wherein the serotonin (5HT) receptor type 1A agonist is selected from the group consisting of 8-OH-DPAT and buspirone.
A method of treating an individual with ALS induced respiratory abnormalities comprising administering a serotonin (5HT) receptor type 1A agonist, wherein the serotonin (5HT) receptor type 1A agonist is selected from the group consisting of 8-OH-DPAT and buspirone.
Dependencies are inferred from the claim text.